Education > XRAY > Ovarian Cancer

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

1 through 10 of 48

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Cancer risks of people with inherited PALB2 mutations

Most relevant for: people with inherited PALB2 mutations

In the largest study of people with inherited PALB2 mutations to date, the gene was linked to increased lifetime risk of breast cancer in women and men, ovarian and pancreatic cancer but not prostate or colorectal cancer. (posted 7/1/21)

Read More
Cancer risks of people with inherited PALB2 mutations

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline

Study : Birth control pills may offer long-term protection against endometrial and ovarian cancer

Most relevant for: People concerned about endometrial, ovarian or breast cancer risk

A large study showed that birth control pills may protect against endometrial and ovarian cancers, even years after use was discontinued. (posted 6/1/21)

Read More
Birth control pills may offer long-term protection against endometrial and ovarian cancer

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Body Mass Index (BMI) may affect how well aspirin use protects against colorectal and ovarian cancer

Most relevant for: People concerned about their risk of colorectal or ovarian cancer.

This study looked at the impact of daily aspirin use for lowering the risk for multiple types of cancers and whether this risk reduction can be modified by cancer risk factors such as obesity, smoking, physical inactivity or a family history of cancer. (3/19/21)

Read More
Body Mass Index (BMI) may affect how well aspirin use protects against colorectal and ovarian cancer

Relevance: Medium-High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Guideline : COVID vaccines for people with cancer

Most relevant for: Cancer patients, their family and caregivers

Should cancer patients get a COVID vaccine? The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) provide guidance for people with cancer. These experts recommend that most cancer patients get vaccinated as soon as the vaccine is offered (unless they are allergic to a vaccine component). Cancer patients who have had recent surgery may delay vaccination a few days after surgery. Those with a suppressed immune system are advised to delay getting the vaccine until they’re healthy enough to do so. (2/1/21)

Este artículo está disponible en español.

Read More
COVID vaccines for people with cancer

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations

Most relevant for: Women considering breastfeeding who have inherited BRCA mutations.

Data from a large-scale study suggests that breastfeeding may protect against ovarian cancer in women with inherited mutations in BRCA1 or BRCA2. (1/28/21)

Este artículo está disponible en español.

Read More
Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Women support delayed removal of ovaries

Most relevant for: Women at high risk of ovarian cancer who are considering undergoing risk-reducing surgery.

Risk-reducing early removal of fallopian tubes followed by removal of ovaries at a later date was acceptable to women at high risk of ovarian cancer due to an inherited mutation in a recent study.  This was especially true for women worried about sexual dysfunction associated with surgical menopause. (12/24/20)

Read More
Women support delayed removal of ovaries

Relevance: High

pointerRelevance

Quality of Writing: High

pointerQuality of Writing
View Related Clinical Trials

Personal Story : Coping with chemotherapy-induced hair loss

Most relevant for: People who receive chemotherapy for cancer treatment

Ovarian cancer survivor Stephanie Hess shared her personal story about how she coped with hair loss. This XRAY review also includes treatments to reduce this common side effect of chemotherapy. (9/28/20)

Read More
Coping with chemotherapy-induced hair loss

Relevance: Medium-High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer

Most relevant for: Women with advanced-stage ovarian cancer

Treatment with veliparib may benefit women with advanced ovarian cancer. A recent clinical trial shows that this new PARP inhibitor may delay progression of cancer when combined with chemotherapy and when continued alone as a maintenance therapy. (8/18/20)

Read More
New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science
View Related Clinical Trials

Update : FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer

Most relevant for: Women with advanced ovarian cancer whose tumor has a BRCA mutation or a type of tumor marker called homologous recombination deficiency (HRD)

The FDA has approved the first drug combination to be used as a first-line maintenance therapy for some women with advanced ovarian cancer. (7/7/2020)

Read More
FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : New FDA approval of PARP inhibitor for maintenance therapy in ovarian cancer

Most relevant for: People with advanced ovarian cancer who have had a complete or partial response to chemotherapy

The FDA has approved the use of niraparib (Zejula) as a maintenance therapy for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy. (5/7/20)

Read More
New FDA approval of PARP inhibitor for maintenance therapy in ovarian cancer

This Portal Sponsored By:

AstraZeneca